Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 84Carcinoma, Non-Small-Cell Lung 56Triple Negative Breast Neoplasms 35Breast Neoplasms 34Neoplasms 28Neoplasm Metastasis 28Colorectal Neoplasms 17Lung Neoplasms 13Carcinoma, Pancreatic Ductal 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Adenocarcinoma 9Stomach Neoplasms 8Melanoma 8Carcinoma 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms by Site 6Fallopian Tube Neoplasms 6Small Cell Lung Carcinoma 5Carcinoma, Squamous Cell 5Peritoneal Neoplasms 4Head and Neck Neoplasms 4Digestive System Neoplasms 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Solid Tumor 3Sarcoma 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Histologic Type 3

Interventions

pembrolizumab 3napabucasin 3Bevacizumab 3entinostat 2Paclitaxel 2Ocoxin 2Leucovorin 2Irinotecan 2Immunotherapy 2Gemcitabine 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vorasidenib 1sipuleucel-T 1pralsetinib 1palbociclib 1luprolide acetate gel depot 1linifanib 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1durvalumab 1catumaxomab 1Vaccines 1VB6-845 fusion protein 1Taxes 1Sorafenib 1Pemetrexed 1Papillomavirus Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Glandular and Epithelial × 130-nm albumin-bound paclitaxel × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡